Evidence map›Paper›PMID 14551748›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2004

Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Mei Tian, Hong Zhang, Yoshiki Nakasone, Kenji Mogi, Keigo Endo

Abstract readClinical TrialValidation Study
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.European journal of nuclear medicine and molecular imaging · 2004
    Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Value of SUVBiology · 2020
    Article
  16. Review
  17. Can the Efficacy of [Pharmaceuticals (Basel, Switzerland) · 2019
    Review
  18. Observational
  19. Article
  20. Ketogenic Diets and Cancer: Emerging Evidence.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mei TianDepartment of Nuclear Medicine and Diagnostic Radiology, Gunma University School of Medicine, 3-39-22 Showa-machi, 371-8511 Maebashi, Gunma, Japan. tian@med.gunma-u.ac.jp
Hong Zhang
Yoshiki Nakasone
Kenji Mogi
Keigo Endo

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased expression of glucose transporter-1 (Glut-1) and glucose transporter-3 (Glut-3) has been reported in many human cancers. The mechanism of glucose entry into oral squamous cell carcinoma (OSCC) remains unclear. In this study we investigated, in untreated human OSCC, the relationship between tumour fluorine-18 fluoro-2-deoxy-D-glucose (FDG) accumulation and the expression of Glut-1 and Glut-3, as well as the association between the expression of Glut-1 and of Glut-3. All patients underwent FDG positron emission tomography (PET) pre-operatively. Standardised uptake values (SUVs) were used for evaluation of tumour FDG uptake. Final diagnoses were established by histology. Immunohistochemical staining results were evaluated according to the percentage (%) of positive area, intensity and staining score. Tumour sections were stained by immunohistochemistry for Glut-1 and Glut-3. Glut-1 immunostaining revealed that 18 (94.7%) of the 19 tumours stained positively, while Glut-3 immunostaining yielded positive findings for 16 (84.2%) tumours. Overall, a relatively low level of agreement (36.8%) in the staining score was observed between Glut-1 and Glut-3 expression. No relationship was found between the staining pattern and tumour differentiation or T grade classification in either Glut-1 or Glut-3 immunostaining. Furthermore, no relationship was found between increased FDG SUV and tumour differentiation, but the former did correlate with T grade. In conclusion, high FDG uptake values were seen in OSCC with overexpression of Glut-1 and Glut-3. However, no significant correlation was found between FDG SUV and Glut-1 or Glut-3 expression.

Indexed as

AgedBiomarkers, TumorCarcinoma, Squamous CellFemaleFluorodeoxyglucose F18Glucose Transporter Type 1Glucose Transporter Type 2HumansMaleMiddle AgedMonosaccharide Transport ProteinsMouth NeoplasmsRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityStatistics as TopicBiomarkers, TumorFluorodeoxyglucose F18Glucose Transporter Type 1Glucose Transporter Type 2Monosaccharide Transport ProteinsRadiopharmaceuticalsSLC2A1 protein, human

Identifiers

PMID14551748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.